Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR ‐615‐3p‐ PICK1 interaction
BioFactors · 2025
DOI: 10.1002/biof.2147 ↗At a glance
Journal article in BioFactors, 2025. Written by Xinyan Jia and 4 co-authors. Institution: College of Basic Medical Science, Jinzhou Medical University, Jinzhou, Liaoning, China. Major MEDLINE topics: MicroRNAs, Vimentin, Breast Neoplasms, Gene Expression Regulation, Neoplastic. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shanghai Pudong New Area Health and Family Planning Commission Leading Talent Training Program, Shanghai Pudong New District Health and Family Planning Commission Industry Specialization, National Natural Science Foundation of China.
Abstract (original language)
Breast cancer continues to be a major health issue for women worldwide, with vimentin (VIM) identified as a crucial factor in its progression due to its role in cell migration and the epithelial‐to‐mesenchymal transition (EMT). This study focuses on elucidating VIM's regulatory mechanisms on the miR‐615‐3p/PICK1 axis. Utilizing the 4T1 breast cancer cell model, we first used RNA‐seq and proteomics to investigate the changes in the APA of PICK1 following VIM knockout (KO). These high‐throughput analyses aimed to uncover the underlying transcriptional and proteomic alterations associated with VIM's influence on breast cancer cells. RNA‐seq and proteomic profiling revealed significant APA in PICK1 following VIM KO, suggesting a novel mechanism by which VIM regulates breast cancer progression. Validation experiments confirmed that VIM KO affects the miR‐615‐3p‐PICK1 axis, with miR‐615‐3p's regulation of PICK1 being contingent upon the APA of PICK1. These findings highlight the complex interplay between VIM, miR‐615‐3p, and PICK1 in the regulation of breast cancer cell behavior. This study reveals that vimentin affects the miR‐615‐3p‐PICK1 axis through APA, revealing the key role of VIM in cancer progression. Opened up new avenues for targeted cancer therapy, with a focus on regulating the interaction between APA and miR‐615‐3p‐PICK1.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Basic Medical Science, Jinzhou Medical University, Jinzhou, Liaoning, China.
- Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, People's Republic of China.
- Department of Breast Surgery, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, People's Republic of China.
- Ji'an Central People's Hospital (Ji'an Hospital of Shanghai East Hospital), Jiangxi Province, China.
ORCID profiles: Chunyan Dong
Funding
- Shanghai Pudong New Area Health and Family Planning Commission Leading Talent Training Program
- Shanghai Pudong New District Health and Family Planning Commission Industry Specialization
- National Natural Science Foundation of China
- the Jiangxi Provincial Key Research and Development Program
Cite
APA
Jia, X., Shao, L., Quan, H., Zhong, Z., & Dong, C. (2025). Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR ‐615‐3p‐ PICK1 interaction. BioFactors. https://doi.org/10.1002/biof.2147
Vancouver
Jia X, Shao L, Quan H, Zhong Z, Dong C. Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR ‐615‐3p‐ PICK1 interaction. BioFactors. 2025. doi:10.1002/biof.2147
BibTeX
@article{Jia2025,
author = {Jia, Xinyan and Shao, Lujing and Quan, Hong and Zhong, Zhixian and Dong, Chunyan},
title = {Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR ‐615‐3p‐ PICK1 interaction},
journal = {BioFactors},
year = {2025},
doi = {10.1002/biof.2147}
}
EUVIMED